

Brain Total Creatine Differs Between Primary Progressive Aphasia (PPA) Subtypes and Correlates with Disease Severity

Kathleen E. Hupfeld^{a,b}, Helge J. Zöllner^{a,b}, Georg Oeltzschner^{a,b}, Hayden W. Hyatt^c, Olivia Herrmann^d, Jessica Gallegos^d, Steve C. N. Hui^{a,b}, Ashley D. Harris^{e,f}, Richard A. E. Edden^{a,b}, and Kyrana Tsapkini^{d,g*}

^a Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA

^b F. M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD, USA

^c Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

^d Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

^e Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada

^f Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada

^g Department of Cognitive Science, Johns Hopkins University, Baltimore, MD, USA

Corresponding Author: Kyrana Tsapkini, PhD
Departments of Neurology and Cognitive Science
Johns Hopkins University
Phipps 488, 600 N Wolfe Street
Baltimore, MD 21287
Email: tsapkini@jhmi.edu

Running Title: BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA

41 **Highlights**

- 42 • No prior work has examined differences in brain metabolite levels for PPA subtypes.
- 43 • Total creatine (tCr) levels were lowest in lvPPA and highest in svPPA.
- 44 • tCr levels differentiated lvPPA from svPPA diagnosis.
- 45 • Higher tCr and lower Glx in the left IFG correlated with greater disease severity.
- 46 • Changes in cellular energy and excitatory processes may relate to PPA pathology.

47 **Abstract**

48 Primary progressive aphasia (PPA) is comprised of three subtypes: logopenic (lvPPA),
49 non-fluent (nfvPPA), and semantic (svPPA). We used magnetic resonance spectroscopy (MRS)
50 to measure tissue-corrected metabolite levels in the left inferior frontal gyrus (IFG) and right
51 sensorimotor cortex (SMC) from 61 PPA patients. We aimed to: 1) characterize subtype
52 differences in metabolites; and 2) test for metabolite associations with symptom severity. tCr
53 differed by subtype across the left IFG and right SMC. tCr levels were lowest in lvPPA and
54 highest in svPPA. tCr levels predicted lvPPA versus svPPA diagnosis. Higher IFG tCr and lower
55 Glx correlated with greater disease severity. As tCr is involved in brain energy metabolism,
56 svPPA pathology might involve changes in specific cellular energy processes. Perturbations to
57 cellular energy homeostasis in language areas may contribute to symptoms. Reduced cortical
58 excitatory capacity (i.e., lower Glx) in language regions may also contribute to symptoms. Thus,
59 tCr may be useful for differentiating between PPA subtypes, and both tCr and Glx might have
60 utility in understanding PPA mechanisms and tracking progression.

61

62 **Keywords:** Primary Progressive Aphasia (PPA), creatine (tCr), glutamate+glutamine (Glx),
63 magnetic resonance spectroscopy (MRS), Point RESolved Spectroscopy (PRESS)

64 **1. Introduction**

65 Primary progressive aphasia (PPA) is a devastating neurodegenerative condition
66 characterized by prominent declines in language function (Gorno-Tempini et al., 2011;
67 Mesulam, 1982). Symptoms usually begin in middle age (around 40-60 years), worsen over
68 time, and may later extend to other cognitive domains (Gorno-Tempini et al., 2011; Grossman,
69 2010; Mesulam, 1982). PPA thus considerably impacts quality of life, in addition to shortening
70 life expectancy; average life expectancy after symptom onset is only about 7-12 years (Tastevin
71 et al., 2021). Critically, aside from some symptom improvement with behavioral therapy
72 (Pagnoni et al., 2021) or neuromodulation (Cotelli et al., 2020; Tsapkini et al., 2018), there
73 remain no disease-modifying treatments for PPA. Therefore, it is becoming increasingly
74 imperative to improve scientific understanding of PPA pathology to identify biomarkers of
75 disease progression as well as potential therapeutic targets.

76 Consistent with their language symptoms, those with PPA typically display cortical
77 atrophy in the left hemisphere, particularly in brain regions related to language function
78 (Rogalski et al., 2014). However, PPA is a heterogeneous disorder associated with both varied
79 symptoms and varied pathology. As such, expert consensus has divided PPA into three main
80 subtypes (Gorno-Tempini et al., 2011) (along with mixed or unclassified cases): 1) logopenic
81 variant PPA (lvPPA) is characterized by deficits in word retrieval (i.e., producing the intended
82 word) and difficulty repeating words and sentences; 2) non-fluent variant PPA (nfvPPA) is
83 characterized by deficits in grammar and speech production and/or slow, effortful, and distorted
84 (apraxic) speech, but preserved word comprehension and naming; and 3) semantic variant PPA
85 (svPPA) is characterized by severe deficits in single-word comprehension and naming, but
86 preserved grammar and fluency (i.e., these individuals tend to produce “empty” speech).

87 These three subtypes have been linked to different cortical atrophy patterns and different
88 pathology. Atrophy is most prominent in the left posterior temporal and inferior parietal lobes in
89 lvPPA, left posterior frontal and fronto-insular cortex in nfvPPA, and anterior temporal lobes (left

90 dominant but usually bilateral) in svPPA (Gorno-Tempini et al., 2011). LvPPA is most often
91 associated with Alzheimer's disease (AD) pathology (e.g., PET-PIB positivity, decreased A β 42,
92 and elevated tau in the cerebrospinal fluid) (Mesulam et al., 2008; Rabinovici et al., 2008),
93 nfvPPA is most often associated with tau-positive pathology (Josephs et al., 2006; Knibb et al.,
94 2006; Mesulam et al., 2008), and svPPA is most often associated with ubiquitin/TDP43-positive
95 frontotemporal lobar degeneration (Davies et al., 2005; Grossman, 2010; Hodges et al., 2004;
96 Mesulam et al., 2008; Nestor et al., 2007). However, there is not a direct correspondence
97 between atrophy or pathology and PPA subtype; thus, further work is warranted to better
98 understand how disease mechanisms might differ between the PPA subtypes.

99 Magnetic resonance spectroscopy (MRS) permits measurement of brain chemicals *in*
100 *vivo* in humans using an MRI scanner and thus can provide insight into potential disease
101 mechanisms and drug targets, distinct from conclusions that can be drawn from the atrophy and
102 pathology measurements discussed above. Standard MRS acquisitions, including short-echo
103 time (TE) Point RESolved Spectroscopy (PRESS), measure metabolites including total *N*-acetyl
104 aspartate (tNAA), total choline (tCho), total creatine (tCr), and glutamate+glutamine (Glx)
105 (Bottomley, 1982). tNAA, a composite measure of NAA and NAAG (N-acetylaspartylglutamate),
106 is a neuronal marker, suggested as an indicator of neuronal density and integrity (Rae, 2014).
107 tCho, the composite of phospholipid precursors phosphocholine (PCh) and
108 glycerophosphocholine (GPC), can reflect changes in membrane turnover or cell density
109 (Cleeland et al., 2019). Creatine and phosphocreatine (reported in combination as tCr) are
110 involved in brain energy metabolism and homeostasis (Rae, 2014). Glx is a combination of two
111 signals: glutamate (i.e., the principal excitatory neurotransmitter in the central nervous system)
112 and glutamine (i.e., a precursor for glutamate). *J*-difference editing of the spectrum using
113 MEScher–GARwood Point RESolved Spectroscopy (MEGA-PRESS) (Choi et al., 2021; Harris et
114 al., 2017; Mescher et al., 1998) allows us to quantify additional metabolites with coupled spin

115 systems and overlapped signals. These include the primary inhibitory neurotransmitter within
116 the central nervous system, gamma-aminobutyric acid (GABA).

117 A majority of studies suggest that brain tNAA, Glx (or glutamate), and GABA levels
118 decrease with normal aging (Chiu et al., 2014; Cleeland et al., 2019; Gao et al., 2013; Haga et
119 al., 2009), and are decreased in mild cognitive impairment (MCI) (Oeltzschner et al., 2019;
120 Zeydan et al., 2017) and AD (Bai et al., 2015; Rupsingh et al., 2011; Wang et al., 2015; Zhang
121 et al., 2014) compared with normal aging. Both tCho and tCr either increase or show no change
122 with normal aging (Chiu et al., 2014; Cleeland et al., 2019; Haga et al., 2009), and are either
123 elevated (Huang et al., 2001; Marjańska et al., 2019) or not different (Marjańska et al., 2019;
124 Wang et al., 2015) in MCI and AD compared with normal aging. Functionally, lower MRS-
125 measured tNAA, Glx (or glutamate), and GABA, and higher tCho, have each been associated
126 with poorer cognitive performance in normal aging (Erickson et al., 2012; Gomar et al., 2014;
127 Kantarci et al., 2011; Porges et al., 2017a; Ross et al., 2005), MCI (Griffith et al., 2007; Lim et
128 al., 2012; Oeltzschner et al., 2019; Riese et al., 2015), AD (Lim et al., 2012), and frontotemporal
129 lobar degeneration patients (Murley et al., 2022). Taken together, it is plausible that these
130 metabolites might differ between the three PPA subtypes and associate with disease severity.

131 We previously identified GABA changes in the left inferior frontal gyrus (IFG) following
132 transcranial direct current stimulation (tDCS) combined with language therapy in PPA patients
133 (Harris et al., 2019). However, the sample size included in this prior work ($n = 22$) was not
134 sufficient to stratify metabolite levels by the three PPA subtypes. Therefore, the objectives of the
135 present study included: 1) to characterize differences in brain metabolite levels between the
136 three PPA subtypes and determine if brain metabolite levels can discriminate between PPA
137 subtypes; and 2) to examine relationships between brain metabolite levels and PPA symptom
138 severity, as indicated by the FrontoTemporal Dementia Clinical Dementia Rating Scale (FTD-
139 CDR, a measure of overall disease severity, including language function, memory, attention,
140 and independence, with scores ranging from 0 (no impairment) to 24 (severe impairment)

141 (Knopman et al., 2008)). We measured MRS metabolites in the left IFG and right sensorimotor
142 cortex (SMC). We selected the left IFG due to its involvement in several language functions
143 such as lexical selection and production, as well as other cognitive functions (Liakakis et al.,
144 2011), evident atrophy in PPA (particularly lvPPA and nfvPPA but also svPPA) (Preiß et al.,
145 2019; Rogalski et al., 2011), and response to tDCS therapy across PPA subtypes (Harris et al.,
146 2019; Tsapkini et al., 2018, 2014). We selected the right SMC (which is involved in sensory
147 processing and motor execution) as a control region. That is, we predicted that brain metabolite
148 levels would differ between PPA subtypes and associate with FTD-CDR scores for the left IFG
149 but not the right SMC.

150

151 **2. Methods**

152 **2.1 Participants**

153 Prior to study enrollment, all patients were evaluated using neurological examination,
154 cognitive and language testing, and neuroimaging. All patients enrolled in the study were
155 diagnosed with PPA using current consensus criteria (Gorno-Tempini et al., 2011); diagnoses
156 were confirmed by expert clinicians. Additional inclusion criteria included: at least a 12th grade
157 education, right-handedness, and English as a first language. Participants were excluded if:
158 they were over 90 years of age, were not pre-morbidly proficient spellers, had progressed to
159 advanced stages of PPA or other dementia, had any diagnosed comorbid neurologic conditions
160 (e.g., stroke, psychiatric, or developmental disorder), or if they had any contraindications for
161 MRI scanning. The Johns Hopkins University Institutional Review Board (#NA_00071337)
162 approved all study procedures, and the trial was registered on ClinicalTrials.gov
163 (NCT02606422). All participants scored >0 on the FTD-CDR scale, indicating at least some
164 level of impairment to daily functioning. All participants also completed the Boston Naming Test
165 (BNT) (Kaplan et al., 2001), Hopkins Assessment on Naming Actions (HANA) (Breining et al.,
166 2015), digit span (forward and backward), Letter Verbal Fluency Test (FAS), Semantic Verbal


167 Fluency Test (fruits, animals, and vegetables), and the Trail Making Test A and B (Tombaugh,
168 1999). Of note, the present work included only PPA patients and not age-matched controls; we
169 expand on the limitations of this study design in the Discussion.

170 **2.2 MRS Acquisition**

171 All MRS data were collected using the same 3.0 Tesla Philips Achieva MRI scanner
172 using a 32-channel head coil. For voxel positioning and tissue segmentation, we first collected a
173 whole-brain T_1 -weighted structural MRI scan, using the following parameters: magnetization-
174 prepared rapid gradient-echo (MPRAGE) sequence, TR/TE = 8 ms/3.75 ms, flip angle = 8°,
175 slice thickness = 1.0 mm, 150 slices, voxel size = 1 mm³ isotropic voxels. Next, immediately
176 after the T_1 , we acquired metabolite spectra from two 30 x 30 x 30 mm³ voxels (Figure 1) using
177 both short-TE PRESS and MEGA-PRESS sequences. We positioned the left IFG voxel using
178 the anatomical landmarks of the lateral ventricles and insula. We positioned the right SMC voxel
179 by centering the voxel on the hand knob in the precentral gyrus. Both voxels were carefully
180 shifted and rotated to avoid the edge of the brain and ventricles as much as possible to avoid
181 lipid contamination and partial-volume effects.

182 To measure tNAA, tCho, tCr, and Glx, we used a standard short-TE PRESS acquisition
183 with the following parameters: TR/TE = 2000 ms/32 ms; 48 averages sampled at 2000 Hz with
184 2048 points; and water suppression using the VAPOR method (Tkáč et al., 1999). To resolve
185 GABA, we used MEGA-PRESS (Harris et al., 2017; Mescher et al., 1998) with the following
186 parameters: TR/TE = 2000 ms/68 ms; 14-ms editing pulses at 1.9 ppm and 7.46 ppm,
187 alternating every 2 averages; 320 averages in total; and VAPOR water suppression (Tkáč et al.,
188 1999). MEGA-PRESS editing schemes for the detection of GABA co-edits homocarnosine and
189 macromolecular signals (Harris et al., 2015a); therefore, as is standard practice, we refer to the
190 edited 3 ppm GABA signal as GABA+ in the remainder of the manuscript. For both the short-TE
191 PRESS and MEGA-PRESS acquisitions, we also collected 8 water reference spectra without

192 water suppression or pre-inversion, for later use in eddy current correction and metabolite
193 quantification.



194
195 **Figure 1. Voxel Placement and Spectra.** (A-B) *In vivo* MR spectra were acquired from the left inferior frontal gyrus
196 (IFG) and right sensorimotor cortex (SMC); each participant's native space binary voxel mask is normalized to
197 standard (MNI) space and overlaid onto the spm152 template. Warmer colors indicate areas of greater overlap
198 between participants (color bar = number of subjects overlapped). (C-D) Average short-TE PRESS and GABA-edited
199 MEGA-PRESS spectra (black), 95% confidence interval (gray shading) and model fits (blue) for all participants for
200 both voxels. The PRESS spectra are shown from 0.2-4.2 ppm. The MEGA-PRESS spectra are shown from 2.7-4.2
201 ppm.
202

203 2.3 MRS Data Processing

204 MRS data were analyzed using the open-source analysis toolbox Osprey (v2.0.0;
205 <https://github.com/schorschinho/osprey/>) (Oeltzschner et al., 2020) within MATLAB R2021b.
206 The analysis procedures followed consensus-recommended processing guidelines for PRESS
207 and MEGA-PRESS data (Choi et al., 2021; Wilson et al., 2019) and match those applied in our
208 previous work (Zöllner et al., 2022, 2021). Briefly, for the short-TE PRESS data, analysis steps
209 included: loading the vendor-native raw data (which had already been coil-combined, eddy-

210 current-corrected, and averaged on the scanner at the time of data collection), removing the
211 residual water signal using a Hankel singular value decomposition (HSVD) filter (Barkhuijsen et
212 al., 1987), and modeling the metabolite peaks as described in detail in (Oeltzschner et al., 2020;
213 Zöllner et al., 2021) using a custom basis set generated by our new MRSCloud tool
214 (<https://braingps.anatomyworks.org/mrs-cloud>; (Hui et al., 2022)). The basis set was generated
215 using PRESS localization at TE = 32 ms with the Philips-specific sequence timing and real RF
216 pulse waveforms, and consisted of simulations of 32 metabolites including NAA and NAAG
217 (=tNAA), Cr and PCr (=tCr), GPC and PCh (=tCho), Glu and Gln (=Glx), and GABA (which are
218 of interest in this study), as well as 23 other low-concentration metabolites. We then created a
219 binary mask of the two MRS voxels in subject space, co-registered these masks to each
220 participant's T_1 -weighted structural scan, and segmented the structural scans using SPM12
221 (Ashburner et al., 2014), and quantified metabolite levels with respect to the unsuppressed
222 water scan. These tissue volume fractions in the MRS voxels were used for full tissue- and
223 relaxation-corrected metabolite quantification (see below).

224 For the GABA-edited MEGA-PRESS data additional, standardized analysis steps in
225 Osprey included: eddy-current correction based on the water reference (Klose, 1990), robust
226 spectral registration (Mikkelsen et al., 2020) to separately align the individual transients within
227 each sub-spectrum, and final alignment of the averaged sub-spectra by minimizing the choline
228 peak in the difference spectrum before generating the final GABA-edited difference spectrum.
229 The co-edited macromolecules (MMs) at 3 ppm were modelled with the "1to1GABA" model,
230 which uses one composite GABA + MM basis function (i.e., the sum of the GABA and MM_{3co}
231 basis functions, with a fixed 1:1 amplitude ratio); this model assumes 50% of the 3-ppm signal in
232 the GABA-edited difference spectrum can be attributed to co-edited MMs (Deelchand et al.,
233 2021; Zöllner et al., 2022). As is standard for 3 T GABA-edited MEGA-PRESS data, we
234 considered the composite edited 3-ppm signal, i.e., "GABA+" (GABA+MM) values in our
235 statistical analyses.

236 Finally, we corrected all metabolite estimates in order to assess metabolite levels only in
237 the tissue present in the voxel, which is particularly relevant for aging and neurodegenerative
238 disease populations who may have substantial cortical atrophy (Maes et al., 2018; Porges et al.,
239 2017b). We applied tissue and relaxation correction to the short-TE PRESS values; this adjusts
240 metabolite estimates to account for atrophy and heterogeneous tissue composition within the
241 voxels, using literature values (Wansapura et al., 1999) to account for differences in water
242 visibility and relaxation times between tissue types (Gasparovic et al., 2006; Harris et al.,
243 2015b). Similarly, to account for the effects of atrophy and tissue-specific water visibility and
244 relaxation, (and assuming that GABA+ levels in gray matter are twice that in white matter), we
245 applied the “alpha” correction to all GABA+ values (Harris et al., 2015b). For further details on
246 MRS data acquisition, processing, and quality, see Appendices A-B, in which we list all
247 consensus-recommended parameters (Lin et al., 2021). For further information on metabolite
248 quantification and the applied tissue correction, see Appendix C.

249 **2.4 Statistical Analyses**

250 We conducted all statistical analyses using R 4.0.0 (R Core Team, 2021) within RStudio
251 (RStudio Team, 2021). First, we used one-way ANOVAs (or Kruskal-Wallis non-parametric tests
252 if the ANOVA assumptions of normality and heteroskedasticity were not met) to test for group
253 differences in demographic variables, symptom severity, cognitive function, and MRS data
254 quality between the three subtypes. Next, we used linear mixed models (*lme*, (Pinheiro and
255 Bates, 2000)) to examine whether metabolite levels differed by PPA subtype or brain region. In
256 the final model, we entered the metabolite level as the outcome variable, PPA subtype and
257 voxel (i.e., IFG or SMC) as predictors, and included a random intercept for each subject (similar
258 to our previous work, (Hupfeld et al., 2021)). Including the PPA subtype*voxel interaction term
259 or a random slope for each subject did not improve model fit (likelihood ratio test $p > 0.05$), so
260 these terms were omitted from the final statistical models. Including age or years since
261 diagnosis as additional predictors in follow-up models did not influence the statistical

262 significance of any results. Each final model satisfied the linear mixed model assumptions of
263 homogeneity of variances and normality of residuals. We used this same linear mixed model
264 approach to test for PPA subtype and brain region differences in bulk tissue composition (i.e.,
265 voxel gray matter, white matter, and cerebrospinal fluid fractions). We conducted a follow-up
266 analysis using two binary logistic regressions to determine whether tCr levels significantly
267 predicted diagnosis (i.e., lvPPA vs. svPPA and lvPPA vs. nvfPPA). Including age or years since
268 diagnosis in these logistic regression models resulted in poorer model fit (higher AIC and BIC)
269 and thus these two predictors were excluded from the final model.

270 Lastly, we applied a linear model to test for relationships between brain metabolite levels
271 and PPA symptom severity (i.e., FTD-CDR scores). Given the subgroup sizes and the missing
272 MRS and FTD-CDR data (see Table B2), we conducted this analysis across the whole cohort
273 instead of stratified by PPA subtype. In addition, given the amount of missing GABA+ data
274 compared with the other metabolites (Table B2), we did not include GABA+ as a predictor in this
275 metabolite-symptom severity model (though we did test for GABA+ differences between PPA
276 subtypes, as described above). Thus, in the full model, we entered as predictors: the metabolite
277 levels from both voxels (4 metabolites/voxel), age, sex, and years since diagnosis. We then
278 selected a final model using *bestglm* with cross-validation, delete-d method, and 1,000
279 replications to produce a final model that retained only the best predictors of FTD-CDR score
280 (McLeod and Xu, 2010; Zhang, 2016). The FTD-CDR scores were not normally distributed
281 (Shapiro test $p < 0.05$), so we reran the same model selection procedure after square root-
282 transforming the FTD-CDR variable, which improved the normality of the data (Shapiro test $p >$
283 0.05).

284
285
286
287
288
289

290 **3. Results**

291 **3.1 Sample Characteristics**

292 The total cohort consisted of 61 PPA patients: 22 lvPPA, 27 nfvPPA, and 12 svPPA.
293 There were no differences in sex, age, time since diagnosis, or symptom severity based on PPA
294 subtype (Table 1). As anticipated (Beales et al., 2019; Gorno-Tempini et al., 2004; Wicklund et
295 al., 2014), svPPA participants performed worst on the tests of naming (i.e., BNT and HANA) and
296 semantic verbal fluency (Fruits, Animals Vegetables), and lvPPA participants performed worst
297 on the Digit Span – Forward and Backward tasks, which assess verbal working memory (Table
298 1). There were no subtype differences for the remaining cognitive tasks (i.e., FAS or Trail
299 Making – A and B tests; Table 1). IFG short-TE PRESS data was not collected for 2
300 participants, IFG MEGA-PRESS data was not collected for 1 participant, and FTD-CDR scores
301 were missing for 7 participants. Table B2 details additional data omissions from statistical
302 analyses; MRS data were excluded if NAA linewidth was greater than 15 Hz (Cao et al., 2018;
303 Deelchand et al., 2021; Mosser and Edwards, 2008; Nwaroh et al., 2020; Sasaki et al., 2021) or
304 if incorrect pulse sequence parameters were used during acquisition. Group mean spectra (after
305 these exclusions) are presented in Figure 1, and spectra for a single exemplar participant are
306 shown in Figure B1. Data quality metrics (i.e., linewidth, SNR, fit error, and drift) are presented
307 for the whole cohort (Appendix A) and by PPA subtype (Appendix B). There were no differences
308 in MRS data quality based on PPA subtype (Table B1).

309 **Table 1.** Sample Characteristics
310

	lvPPA	nfvPPA	svPPA	F or χ^2	p	η^2
<i>n</i>	22	27	12	--	--	--
Sex	13 F; 9 M	11 F; 16 M	7 F; 5 M	1.97	0.373	--
Age (years)	65.55 (8.12)	68.59 (6.62)	68.67 (5.25)	1.36	0.265	0.04
Years of education ^{a,b}	16.48 (1.91)	16.83 (2.44)	16.35 (2.33)	0.23	0.799	0.01
Years since diagnosis ^{a,c}	3.93 (2.83)	3.81 (2.58)	5.05 (2.91)	0.83	0.442	0.03
FTD-CDR sum score ^{a,d}	6.55 (5.17)	5.26 (4.17)	7.61 (5.59)	0.87	0.424	0.03
Boston Naming Test (BNT) ^{a,e}	19.19 (9.03)	22.00 (8.09)	4.00 (3.95)	20.68	< 0.001***	0.43
Hopkins Assessment on Naming Actions (HANA) ^{a,f}	20.90 (9.72)	24.28 (9.62)	9.10 (6.74)	9.72	< 0.001***	0.27
Letter Verbal Fluency (FAS) ^{a,h}	18.77 (12.38)	16.58 (10.22)	21.90 (15.44)	0.73	0.487	0.03
Semantic Verbal Fluency (Fruits, Animals, Vegetables) ^h	20.73 (13.48)	22.00 (12.75)	10.10 (7.40)	3.55	0.036*	0.11
Digit Span – Forward ^g	3.82 (1.82)	4.58 (1.64)	6.35 (1.76)	7.36	0.001**	0.21
Digit Span – Backward ^g	2.36 (1.15)	2.96 (1.24)	4.80 (1.70)	12.29	< 0.001***	0.31
Trail Making Test - A ^{a,i}	98.18 (97.26)	53.96 (21.14)	47.89 (17.90)	3.14	0.053	0.12
Trail Making Test - B ^{a,i}	233.12 (85.03)	196.11 (89.90)	147.89 (96.74)	2.71	0.078	0.11

311 *Table 1 Note.* For each metric, we report the mean (standard deviation) for each PPA subtype. We also report the
312 results of one-way ANOVAs to characterize differences in each variable between the subtype groups. For sex, we
313 report the number of males (M) and females (F) and the result of a Pearson's chi-square test for differences in the
314 sex distribution within each group. This table includes all available participants; however, statistical analyses of MRS
315 data omitted several additional participants (see Table B2). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.
316
317

318 ^a In cases where the variable did not meet the one-way ANOVA assumptions of homogeneity of variances between
319 groups, independence of residuals, and/or normality of residuals (indicated by the subscript 'a'), we reran each
320 analysis using the non-parametric Kruskal-Wallis test. In all cases, the non-parametric test did not change the
321 statistical significance of the result.
322

323 ^b Years of education was unavailable for 1 lvPPA, 3 nfvPPA, and 2 svPPA patients.
324

325 ^c Years since diagnosis was unavailable for 1 lvPPA, 3 nfvPPA, and 1 svPPA patients.
326

327 ^d FTD-CDR sum score was unavailable for 4 nfvPPA patients and 3 svPPA patients.
328

329 ^e BNT was scored out of 30 possible points. BNT score was unavailable for 1 lvPPA, 2 nfvPPA, and 1 svPPA patient.
330

331 ^f HANA was scored out of 35 possible points. HANA score was unavailable for 1 lvPPA, 2 nfvPPA, and 2 svPPA
332 patients.
333

334 ^g Digit Span – Forward and Backward were scored out of 9 possible points each. Digit span scores were unavailable
335 for 1 nfvPPA patient and 2 svPPA patients.
336

337 ^h FAS and Fruits, Animals, Vegetables were scored as the number of words the participant could name starting with
338 the letters F, A, and S or in each fruit/animal/vegetable category (1 minute for each trial). These scores were
339 unavailable for 1 nfvPPA patient and 2 svPPA patients.
340

341 ⁱ Trail Making Test – A and B scores are in seconds required to complete the task. Trail Making Test – B was
342 terminated after 300 seconds. Trail Making Test scores were unavailable for 5 lvPPA, 6 nfvPPA, and 3 svPPA
343 patients.
344

345 3.2 Differences in Brain Metabolite Levels by PPA Subtype

346 tCr levels differed by subtype across both voxels; svPPA patients had higher mean tCr

347 compared with lvPPA patients ($p = 0.019$; Figure 2; Table 2). nfvPPA patients had higher mean


348 tCr levels compared with lvPPA patients, though this difference did not reach statistical
349 significance within the linear mixed effects model ($p = 0.071$; Figure 2; Table 2). Including age in
350 this model did not change the statistical significance of any results (svPPA vs. lvPPA: $p = 0.045$;
351 nfvPPA vs. lvPPA: $p = 0.175$). However, age was also a significant predictor of tCr levels; older
352 age was associated with greater tCr levels ($p = 0.011$). There were no other differences in brain
353 metabolite levels (all $p > 0.05$; Figure 2; Table 2) or voxel tissue fractions (all $p > 0.05$; Table
354 B4) based on PPA subtype. Moreover, there were no associations between years since
355 diagnosis and any metabolite levels (all $p > 0.05$).

356 Comparing lvPPA and svPPA, the follow-up binary logistic regression model revealed a
357 statistically significant association between diagnosis and tCr levels (odds ratio: 3.08; 95%
358 confidence interval: 1.46-7.21; $p = 0.005$). Comparing lvPPA and nfvPPA, the association
359 between diagnosis and tCr levels was not statistically significant (odds ratio: 1.72; 95%
360 confidence interval: 1.00-3.12; $p = 0.062$). Including age and years since diagnosis in these
361 models did not improve model fit (higher AIC and BIC), and these predictors were not
362 statistically significant indicators of PPA subtype ($p > 0.05$ in all cases).

363 **3.3 Regional Differences in Brain Metabolites and Voxel Composition**

364 tNAA was lower in the IFG compared with the SMC ($p < 0.001$), while tCho, tCr, and Glx
365 were higher in the IFG compared with the SMC (all $p < 0.001$; Figure 2; Table 2). GABA+ did
366 not differ by brain region ($p = 0.626$; Figure 2; Table 2). The IFG compared with the SMC voxel
367 had a higher gray matter ($p < 0.001$) and lower white matter fraction ($p < 0.001$), as well as a
368 greater total tissue fraction (i.e., higher gray matter + white matter fraction; $p = 0.012$; Table B4).

BRAIN CREATINE IN PRIMARY PROGRESSIVE APHASIA



368
371
372
373
374
375
376
377

Figure 2. Differences in Metabolites by PPA Subtype and Brain Region. Metabolite levels for the lvPPA (pink), nfvPPA (green), and svPPA (blue) subtypes are shown for the IFG (left) and SMC (right) voxels. * indicates $p < 0.05$ for the comparison of svPPA tCr levels with lvPPA tCr levels. *** indicates $p < 0.001$ for the comparison of metabolite values within the SMC versus the IFG.

Table 2. Differences in Metabolites by PPA Subtype and Brain Region

Predictors	Estimates (SE)	CI	t	p
tNAA (i.u.)				
Diagnosis (nfvPPA)	-0.53 (0.33)	-1.19-0.12	-1.60	0.115
Diagnosis (svPPA)	-0.17 (0.41)	-0.98-0.64	-0.41	0.684
Voxel (SMC)	2.58 (0.19)	2.20-2.95	13.44	< 0.001***
tCho (i.u.)				
Diagnosis (nfvPPA)	0.11 (0.09)	-0.07-0.28	1.22	0.227
Diagnosis (svPPA)	-0.12 (0.11)	-0.34-0.09	-1.12	0.269
Voxel (SMC)	-0.26 (0.05)	-0.35-(-0.16)	-5.38	< 0.001***
tCr (i.u.)				
Diagnosis (nfvPPA)	0.34 (0.18)	-0.02-0.69	1.84	0.071
Diagnosis (svPPA)	0.54 (0.23)	0.10-0.99	2.40	0.019*
Voxel (SMC)	-0.40 (0.11)	-0.61-(-0.19)	-3.78	< 0.001***
Glx (i.u.)				
Diagnosis (nfvPPA)	0.91 (0.60)	-0.27-2.09	1.51	0.136
Diagnosis (svPPA)	0.01 (0.74)	-1.45-1.47	0.01	0.988
Voxel (SMC)	-2.58 (0.33)	-3.23-(-1.93)	-7.79	< 0.001***
GABA+ (i.u.)				
Diagnosis (nfvPPA)	-0.10 (0.28)	-0.65-0.45	-0.37	0.716
Diagnosis (svPPA)	0.10 (0.36)	-0.60-0.80	0.28	0.782
Voxel (SMC)	-0.11 (0.23)	-0.57-0.34	-0.49	0.626


378
379
380
381
382

Table 2 Note. Here we report the results of a linear mixed effects model testing for PPA subtype and voxel differences in each metabolite. lvPPA and IFG served as the reference groups. For ease of interpretation, in this table we included only the predictors of interest; see Table B3 for all model and fit information. SE = standard error; CI = 95% confidence interval. * $p < 0.05$, *** $p < 0.001$.

383

384 3.4 Metabolite Relationships with PPA Symptom Severity

385 We included all short-TE PRESS metabolite levels from both voxels (i.e., 4
386 measures/voxel), age, sex, PPA subtype, and years since diagnosis in the full statistical model,
387 and only those participants without missing short-TE PRESS or FTD-CDR data ($n = 49$; see
388 Table B2). The final model retained left IFG tCr, left IFG Glx, and years since diagnosis as
389 statistically significant predictors of FTD-CDR score (Table 3). That is, across the whole cohort,
390 worse PPA symptoms (i.e., higher FTD-CDR scores) were associated with higher left IFG tCr
391 levels (partial $r = 0.39$; $p = 0.007$; Figure 3), lower left IFG Glx levels (partial $r = -0.36$; $p = 0.012$;
392 Figure 3), and longer disease duration (partial $r = 0.34$; $p = 0.021$). Rerunning this model with
393 the square root of FTD-CDR scores as the outcome variable (to meet the normality assumption)
394 returned the same three predictors and did not change the statistical significance of any results.
395 Requiring that age and PPA subtype be included in the model did not change the statistical
396 significance of the metabolite or disease duration predictors, and neither age ($p = 0.529$) nor
397 PPA subtype (nfvPPA vs. lvPPA: $p = 0.224$; svPPA vs. lvPPA: $p = 0.483$) were significant
398 predictors of FTD-CDR score.



399

400 **Figure 3. Relationship of IFG tCr and Glx with FTD-CDR Score.** This figure depicts the partial correlations of tCr
401 and Glx levels in the left IFG with FTD-CDR scores across all participants (lvPPA = pink, nvPPA = green, svPPA =
402 blue). These partial correlations account for the effects of the other predictors included in the final statistical model on
403 the variable of interest (i.e., tCr values are corrected for Glx and years since diagnosis, and Glx values are corrected
404 for tCr and years since diagnosis). Higher FTD-CDR scores indicate worse PPA symptom severity. These plots
405 include $n = 49$ individuals, after exclusion of missing and unusable data (see Table B2).
406

407 **Table 3. Metabolites Relationships with PPA Symptom Severity**
408

Predictors	Estimates (SE)	CI	t	p	R ² / R ² Adjusted
(Intercept)	-14.18 (9.19)	-32.69-4.32	-1.54	0.130	
IFG tCr (i.u.)	1.96 (0.69)	0.57-3.35	2.84	0.007**	
IFG Glx (i.u.)	-0.55 (0.21)	-0.98-(-0.13)	-2.61	0.012*	
Years since diagnosis	0.48 (0.20)	0.08-0.89	2.39	0.021*	

0.34 / 0.29

409
410 *Table 3 Note.* Here we report the results of the final linear model testing for associations between brain metabolite
411 levels and FTD-CDR (i.e., PPA symptom severity) scores. SE = standard error; CI = 95% confidence interval.
412 * $p < 0.05$, ** $p < 0.01$.
413

414 415 **4. Discussion**

416 This is the first study to investigate brain metabolite differences between PPA subtypes
417 using MRS. Our key findings included, firstly, that tissue-corrected tCr differed by PPA subtype
418 across the left IFG and right SMC; lvPPA patients had the lowest tCr levels, followed by nvPPA,
419 and svPPA patients with the highest brain tCr levels. Moreover, tCr levels significantly
420 differentiated between lvPPA and svPPA diagnosis. Secondly, higher tissue-corrected tCr and
421 lower Glx levels in the left IFG (i.e., a brain region critical for language function) were associated
422 with more severe symptoms as indicated by the FTD-CTR scale (which indexes language
423 function as well as other cognitive and daily living domains (Knopman et al., 2008)). Together,
424 these results suggest that brain tCr may play a role in PPA pathology or progression,
425 particularly for the svPPA subtype, and could have utility for differentiating svPPA from other
426 PPA subtypes. Both tCr and Glx might be explored as biomarkers for tracking disease severity
427 and progression.

428 **4.1 Higher tCr Levels in svPPA**

429 Those with svPPA had the highest tCr levels across both the left IFG and right SMC.
430 The creatine (Cr)/phosphocreatine (PCr) system is a short-lived energetic system that allows
431 exchange of high-energy phosphate between Cr, adenosine triphosphate (ATP), and adenosine

432 diphosphate (ADP) via creatine kinase, the primary enzyme in the Cr system. The Cr/PCr
433 system simultaneously supplies a high-energy pool capable of rapidly regenerating ATP during
434 high energetic demands, while also dispersing ATP across the cell to connect ATP consumption
435 to the site of energy production (Bürklen et al., 2006). Cr is found in the highest concentrations
436 in tissues with high ATP demand, including muscle and brain tissue (Rackayova et al., 2017;
437 Rae, 2014). In the present work, we measured tCr (i.e., the sum of Cr and PCr); tCr is thus
438 reflective of the Cr/PCr system more generally, including PCr anabolism, Cr degradation, and Cr
439 extracellular transport.

440 Previous MRS studies have reported elevated tCr in normal aging (Chang et al., 1996;
441 Charlton et al., 2007; Chiu et al., 2014; Cleeland et al., 2019; Haga et al., 2009; Pfefferbaum et
442 al., 1999; Reyngoudt et al., 2012), MCI and AD (Huang et al., 2001), and other neurological
443 conditions with cognitive symptoms (e.g., HIV-positive patients with neurological symptoms
444 (Chang et al., 2003, 2002)). It remains unclear whether this is due to increased Cr and/or PCr
445 synthesis, or decreased clearance of these metabolites from the brain (Chang et al., 1996).
446 Elevated tCr in svPPA could also represent gliosis (Ratai et al., 2011; Reyngoudt et al., 2012;
447 Saunders et al., 1999). tCr concentration in glial cells is about 2-4x that of neurons (Urenjak et
448 al., 1993), and prior work has found an association between higher tCr in non-human primates
449 and more severe gliosis (Ratai et al., 2011) and an association between PPA and accumulation
450 of activated microglia in both gray (Kim et al., 2016) and white matter (Ohm et al., 2019). In
451 addition, activated microglia have been reported to occur close to pathologic insults such as
452 TDP43 inclusions in PPA patients with TDP43-positive pathology (Kim et al., 2016), i.e., the
453 pathology most associated with svPPA (Gorno-Tempini et al., 2011).

454 It is also plausible that higher tCr in svPPA could be a compensatory response to
455 reduced neuronal mitochondrial trafficking (i.e., movement of new mitochondria from the soma
456 to distal axons (Cheng and Sheng, 2021)). Mitochondria are anchored in the cell by syntaphilin
457 (SNPH) (Kang et al., 2008), which is elevated in TDP43-positive frontotemporal lobar

458 degeneration (Andres-Benito et al., 2019), the pathology most associated with svPPA (Gorno-
459 Tempini et al., 2011)). Elevated SNPH in svPPA could result in decreased mitochondrial
460 motility, resulting in a greater need to disperse high-energy phosphate across the cell and thus
461 elevated neuronal Cr. In support of this, neurons lacking appropriate mitochondrial trafficking
462 machinery have reduced ability to form long dendrites, but this is rescued with Cr
463 supplementation (Fukumitsu et al., 2015). Thus, while several mechanisms may contribute to
464 the observed higher tCr levels in svPPA, the specific underlying cause requires further study.

465 **4.2 Lower tCr Levels in lvPPA**

466 It also remains unclear why tCr levels were the lowest for lvPPA patients. Though left
467 IFG atrophy is reported to be more pronounced for lvPPA compared with svPPA (Preiß et al.,
468 2019), we found tCr differences by PPA subtype across both left IFG and right SMC, suggesting
469 more global tCr differences (not specific to one brain region). It is perhaps counterintuitive that
470 tCr levels were lowest for lvPPA patients, given that lvPPA is most closely associated with AD
471 pathology (Mesulam et al., 2008; Rabinovici et al., 2008) and tCr is elevated in AD compared
472 with healthy controls (Huang et al., 2001). It is possible that the reported lvPPA tCr levels are in
473 a similar range to those with AD. Though we are unaware of any studies which directly compare
474 tCr levels in AD versus (lv)PPA patients, recent work found no differences in MRS-measured
475 NAA and ml levels between AD and PPA patients (Mitolo et al., 2021), suggesting that certain
476 brain metabolite levels might be similar between these two neurodegenerative conditions.
477 However, without AD or control groups in the present work, we are unable to make such direct
478 comparisons.

479 **4.3 No PPA Subtype Differences for Other Neurometabolites**

480 We identified differences in brain metabolite levels by PPA subtype only for tCr, but not
481 for the other four investigated metabolites. The metabolite values reported here are corrected
482 for bulk tissue concentrations (Gasparovic et al., 2006; Harris et al., 2015b); that is, we report
483 metabolite values only within the brain tissue that remains in the voxels, accounting for age-

484 related atrophy of gray and white matter. Therefore, our results are not likely explained entirely
485 by subtype differences in atrophy location and severity. Moreover, as we did not identify PPA
486 subtype differences in tNAA levels, it is less likely that tCr subtype differences were driven only
487 by diffuse neuronal loss. Instead, we predict that these subtype differences in tCr are more
488 related to differences in brain energy metabolism, though this hypothesis warrants further
489 investigation in larger cohorts which include healthy aging controls.

490 **4.4 tCr and Glx Associations with PPA Symptoms**

491 We found that both higher tCr and lower Glx levels correlated with more severe PPA
492 symptoms, as indicated by the FTD-CDR inventory. This suggests that higher brain tCr and
493 lower brain Glx levels could be (directly or indirectly) related to maladaptive disease processes.
494 These brain-behavior relationships occurred only for the left IFG but not the right SMC. The
495 regional specificity of this association is plausible (and was hypothesized), as the FTD-CDR
496 inventory includes both language and cognitive function sections; the left IFG is involved in
497 language selection and production (e.g., both oral and written naming and spelling), as well as
498 other cognitive functions (e.g., articulatory loop in working memory) (Liakakis et al., 2011), while
499 the SMC roles are mostly related to motor execution and sensory processing. Higher tCr levels
500 might indicate disruptions in underlying cellular bioenergetic processes, which could contribute
501 to the development of more severe language and other cognitive symptoms in PPA patients;
502 however, such claims warrant further replication in future studies with larger samples, as well as
503 exploration of tCr relationships with additional cognitive metrics.

504 While higher tCr correlated with more severe PPA symptoms, higher brain tCr levels
505 might not be entirely dysfunctional; the relationship between tCr and PPA disease processes
506 could be more complex. Oral Cr supplementation has been shown to improve cognitive function
507 in normal adults (Avgerinos et al., 2018) (though results differed by cognitive domain, effect
508 sizes were small to moderate, and no large-scale Cr supplementation studies have been
509 conducted in PPA patients). Moreover, multiple prior studies have reported *lower* tCr levels or

510 no difference in tCr levels for normal aging cohorts (Cleeland et al., 2019). While these studies
511 used varying methods (e.g., different MRI scanner field strengths and different brain regions), it
512 remains unclear what other factors might influence brain tCr changes in aging and disease.
513 Moreover, as we were unable to include an age-matched control group in the present study, it
514 could be that the tCr levels we report for the PPA patients do not differ significantly from those
515 of normal aging.

516 Prior work has identified relationships between lower Glx (or glutamate) and poorer
517 cognitive and visuomotor performance in both normal aging (Levin et al., 2019; Zahr et al.,
518 2013) and neurodegenerative disease (i.e., MCI (Oeltzschner et al., 2019; Zeydan et al., 2017)
519 and frontotemporal lobar degeneration (Murley et al., 2022, 2020)). Reduced Glx could indicate
520 loss of glutamatergic neurons or disturbances in glutamate and/or glutamine synthesis, which
521 could each reasonably contribute to poorer functional performance. Moreover, as glutamate is a
522 component involved in the synthesis of glutathione (i.e., one of the most abundant brain
523 antioxidants), it could also be that increased brain oxidative stress in response to disease
524 processes would result in greater glutathione production (Duffy et al., 2014; Hupfeld et al.,
525 2021), and thus lower detectable brain glutamate levels. In our cohort, tCr was not correlated
526 with Glx levels in either the IFG (Pearson $r = -0.04$; $p = 0.782$) or SMC (Pearson $r = 0.13$; $p =$
527 0.383), and thus each metabolite may distinctly contribute (directly or indirectly) to PPA disease
528 processes. Further investigation is warranted to better understand the precise mechanisms by
529 which tCr and Glx might each associate with PPA symptoms and progression.

530 **4.5 Limitations**

531 There are several limitations to this work. Our cross-sectional approach precluded us
532 from assessing how these metabolite levels may alter prior to PPA onset and with disease
533 progression. Though years since diagnosis did not differ between subtypes and was distinct
534 from the tCr and Glx relationships with symptom severity, it still could be that disease
535 progression rather than subtype more strongly influences brain metabolite levels. PPA is

536 relatively rare and difficult to diagnose (Knopman et al., 2008); thus, we were unable to compare
537 individuals at the same stage in their disease progression. Similarly, though age did not differ
538 between subtypes and was distinct from the subtype differences in tCr levels, the reported tCr
539 levels in PPA may not differ substantially from normal aging. We were unable to address this
540 question due to the lack of a normal aging control group. There were no differences in the
541 relationship between tCr and symptom severity based on PPA subtype, though all groups
542 trended in the same direction; however, we were likely underpowered to investigate any group
543 differences in this brain-behavior relationship.

544 In addition, there are several limitations to the MRS methods used. Our methods do not
545 allow us to distinguish the contribution of PCr versus Cr to the tCr signal, or the contribution of
546 glutamate versus glutamine to the Glx signal. The tissue corrections applied here are standard
547 for aging cohorts with cortical atrophy (Gasparovic et al., 2006; Harris et al., 2015b); however,
548 these corrections use literature values (Wansapura et al., 1999) for relaxation constants.
549 Changes in water and metabolite relaxation rates with aging and disease could also impact
550 metabolite quantification (Deelchand et al., 2020; Marjańska et al., 2017, 2013), though these
551 were not quantified and thus could not be incorporated into our tissue corrections. The short-TE
552 PRESS data were averaged on the scanner (instead of collecting individual spectra); therefore,
553 frequency drift correction could not be performed on the short-TE PRESS data. It is
554 recommended that future studies use post-processing drift corrections for all MRS data. PPA
555 patients often have more difficulty than others remaining still in the scanner, which could have
556 affected spectral quality (though we excluded any participants with NAA linewidth > 15 Hz);
557 moreover, ability to complete an MRI scan precluded us from enrolling any extremely advanced
558 PPA cases in this cohort.

559 **5. Conclusions**

560 We found that brain tCr differs between PPA subtypes. tCr is highest for svPPA patients,
561 and brain tCr levels differentiate svPPA from lvPPA diagnosis. We also found a correlation

562 between both higher left IFG tCr levels and lower left IFG Glx levels and more severe PPA
563 symptoms. These results suggest that tCr may be useful in differentiating between PPA
564 subtypes, and that both tCr and Glx could have utility as markers of PPA symptom severity.
565 However, further work in larger cohorts which include a normal aging control group is needed to
566 better understand the potential roles of tCr and Glx in PPA development and progression.

567 **Ethics Approval and Consent to Participate**

568 The Johns Hopkins University Institutional Review Board (#NA_00071337) approved all
569 study procedures, and written informed consent was obtained from all participants.

570 **Consent for Publication**

571 All authors consent to the publication of this study.

572 **Availability of Data and Material**

573 The raw data supporting the conclusions of this manuscript will be made available by the
574 authors without undue reservation.

575 **Competing Interests**

576 All authors declare that they have no competing interests.

577 **Funding**

578 This work was supported by grants from the National Institute on Aging (K00 AG068440-
579 03 to KH, R00 AG062230 to GO, and R01 DC014475-05 and R01 AG068881-02 to KT) and
580 grants from the National Institute of Biomedical Imaging and Bioengineering (R01 EB016089 to
581 RE, and P41 EB031771).

582 **Author Contributions**

583 KH analyzed the MRS data, conducted all statistical analyses, created all figures and
584 supplemental material, and wrote the first draft of the manuscript. HZ, GO, SH, AH, and RAE
585 consulted on MRS data analyses and interpretation. HH contributed to manuscript writing and
586 results interpretation. OH, JG, AH, and KT facilitated MRS and behavioral data collection. KT
587 and RAE designed the project and led interpretation and discussion of the results. All authors
588 participated in revision of the manuscript.

589 **Acknowledgements**

590 The authors also wish to thank all of the participants who volunteered their time, without
591 whom this project would not have been possible.

592 **References**

- 593 Andres-Benito, P., Gelpi, E., Povedano, M., Ausin, K., Fernandez-Irigoyen, J., Santamaría, E.,
594 Ferrer, I., 2019. Combined transcriptomics and proteomics in frontal cortex area 8 in
595 frontotemporal lobar degeneration linked to C9orf72 expansion. *J. Alzheimers Dis.* 68,
596 1287–1307.
- 597 Ashburner, J., Barnes, G., Chen, C.-C., Daunizeau, J., Flandin, G., Friston, K., Kiebel, S.,
598 Kilner, J., Litvak, V., Moran, R., 2014. SPM12 manual. Wellcome Trust Cent.
599 Neuroimaging Lond. UK 2464, 4.
- 600 Avgerinos, K.I., Spyrou, N., Bougioukas, K.I., Kapogiannis, D., 2018. Effects of creatine
601 supplementation on cognitive function of healthy individuals: A systematic review of
602 randomized controlled trials. *Exp. Gerontol.* 108, 166–173.
- 603 Bai, X., Edden, R.A., Gao, F., Wang, G., Wu, L., Zhao, B., Wang, M., Chan, Q., Chen, W.,
604 Barker, P.B., 2015. Decreased γ -aminobutyric acid levels in the parietal region of
605 patients with Alzheimer's disease. *J. Magn. Reson. Imaging* 41, 1326–1331.
- 606 Barkhuijsen, H., De Beer, R., Van Ormondt, D., 1987. Improved algorithm for noniterative time-
607 domain model fitting to exponentially damped magnetic resonance signals. *J. Magn.*
608 *Reson.* 1969 73, 553–557.
- 609 Beales, A., Whitworth, A., Cartwright, J., Panegyres, P.K., Kane, R.T., 2019. Profiling sentence
610 repetition deficits in primary progressive aphasia and Alzheimer's disease: Error patterns
611 and association with digit span. *Brain Lang.* 194, 1–11.
612 <https://doi.org/10.1016/j.bandl.2019.03.001>
- 613 Bottomley, P., 1982. Selective volume method for performing localized NMR spectroscopy.
614 US4480228A.
- 615 Breining, B., Tippett, D., Davis, C., Posner, J., Sebastian, R., Oishie, K., Hillis, A., 2015.
616 Assessing dissociations of object and action naming in acute stroke, in: *Clinical*
617 *Aphasiology Conference*.
- 618 Bürklen, T.S., Schlattner, U., Homayouni, R., Gough, K., Rak, M., Szeghalmi, A., Wallimann, T.,
619 2006. The creatine kinase/creatine connection to alzheimer's disease: CK Inactivation,
620 APP-CK complexes and focal creatine deposits. *J. Biomed. Biotechnol.* 2006.
- 621 Cao, G., Edden, R.A.E., Gao, F., Li, H., Gong, T., Chen, W., Liu, X., Wang, G., Zhao, B., 2018.
622 Reduced GABA levels correlate with cognitive impairment in patients with relapsing-
623 remitting multiple sclerosis. *Eur. Radiol.* 28, 1140–1148. [https://doi.org/10.1007/s00330-](https://doi.org/10.1007/s00330-017-5064-9)
624 [017-5064-9](https://doi.org/10.1007/s00330-017-5064-9)
- 625 Chang, L., Ernst, T., Poland, R.E., Jenden, D.J., 1996. In vivo proton magnetic resonance
626 spectroscopy of the normal aging human brain. *Life Sci.* 58, 2049–2056.
- 627 Chang, L., Ernst, T., Witt, M.D., Ames, N., Gaiefsky, M., Miller, E., 2002. Relationships among
628 brain metabolites, cognitive function, and viral loads in antiretroviral-naive HIV patients.
629 *Neuroimage* 17, 1638–1648.
- 630 Chang, L., Ernst, T., Witt, M.D., Ames, N., Walot, I., Jovicich, J., DeSilva, M., Trivedi, N., Speck,
631 O., Miller, E.N., 2003. Persistent brain abnormalities in antiretroviral-naive HIV patients 3
632 months after HAART. *Antivir. Ther.* 8, 17–26.
- 633 Charlton, R.A., McIntyre, D.J.O., Howe, F.A., Morris, R.G., Markus, H.S., 2007. The relationship
634 between white matter brain metabolites and cognition in normal aging: the GENIE study.
635 *Brain Res.* 1164, 108–116.
- 636 Cheng, X.-T., Sheng, Z.-H., 2021. Developmental regulation of microtubule-based trafficking
637 and anchoring of axonal mitochondria in health and diseases. *Dev. Neurobiol.* 81, 284–
638 299.
- 639 Chiu, P.-W., Mak, H.K.-F., Yau, K.K.-W., Chan, Q., Chang, R.C.-C., Chu, L.-W., 2014. Metabolic
640 changes in the anterior and posterior cingulate cortices of the normal aging brain: proton
641 magnetic resonance spectroscopy study at 3 T. *Age* 36, 251–264.

- 642 Choi, I.-Y., Andronesi, O.C., Barker, P., Bogner, W., Edden, R.A., Kaiser, L.G., Lee, P.,
643 Marjańska, M., Terpstra, M., de Graaf, R.A., 2021. Spectral editing in 1H magnetic
644 resonance spectroscopy: Experts' consensus recommendations. *NMR Biomed.* 34,
645 e4411.
- 646 Cleeland, C., Pipingas, A., Scholey, A., White, D., 2019. Neurochemical changes in the aging
647 brain: A systematic review. *Neurosci. Biobehav. Rev.* 98, 306–319.
- 648 Cotelli, M., Manenti, R., Ferrari, C., Gobbi, E., Macis, A., Cappa, S.F., 2020. Effectiveness of
649 language training and non-invasive brain stimulation on oral and written naming
650 performance in Primary Progressive Aphasia: A meta-analysis and systematic review.
651 *Neurosci. Biobehav. Rev.* 108, 498–525.
- 652 Davies, R.R., Hodges, J.R., Kril, J.J., Patterson, K., Halliday, G.M., Xuereb, J.H., 2005. The
653 pathological basis of semantic dementia. *Brain* 128, 1984–1995.
- 654 Deelchand, D.K., Marjańska, M., Henry, P.-G., Terpstra, M., 2021. MEGA-PRESS of GABA+:
655 influences of acquisition parameters. *NMR Biomed.* 34, e4199.
- 656 Deelchand, D.K., McCarten, J.R., Hemmy, L.S., Auerbach, E.J., Eberly, L.E., Marjańska, M.,
657 2020. Changes in the intracellular microenvironment in the aging human brain.
658 *Neurobiol. Aging* 95, 168–175.
- 659 Duffy, S.L., Lagopoulos, J., Hickie, I.B., Diamond, K., Graeber, M.B., Lewis, S.J., Naismith, S.L.,
660 2014. Glutathione relates to neuropsychological functioning in mild cognitive impairment.
661 *Alzheimers Dement.* 10, 67–75.
- 662 Erickson, K.I., Weinstein, A.M., Sutton, B.P., Prakash, R.S., Voss, M.W., Chaddock, L., Szabo,
663 A.N., Mailey, E.L., White, S.M., Wojcicki, T.R., 2012. Beyond vascularization: aerobic
664 fitness is associated with N-acetylaspartate and working memory. *Brain Behav.* 2, 32–
665 41.
- 666 Fukumitsu, K., Fujishima, K., Yoshimura, A., Wu, Y.K., Heuser, J., Kengaku, M., 2015.
667 Synergistic action of dendritic mitochondria and creatine kinase maintains ATP
668 homeostasis and actin dynamics in growing neuronal dendrites. *J. Neurosci.* 35, 5707–
669 5723.
- 670 Gao, F., Edden, R.A., Li, M., Puts, N.A., Wang, G., Liu, C., Zhao, B., Wang, H., Bai, X., Zhao,
671 C., 2013. Edited magnetic resonance spectroscopy detects an age-related decline in
672 brain GABA levels. *Neuroimage* 78, 75–82.
- 673 Gasparovic, C., Song, T., Devier, D., Bockholt, H.J., Caprihan, A., Mullins, P.G., Posse, S.,
674 Jung, R.E., Morrison, L.A., 2006. Use of tissue water as a concentration reference for
675 proton spectroscopic imaging. *Magn. Reson. Med. Off. J. Int. Soc. Magn. Reson. Med.*
676 55, 1219–1226.
- 677 Gomar, J.J., Gordon, M.L., Dickinson, D., Kingsley, P.B., Uluğ, A.M., Keehlisen, L., Huet, S.,
678 Buthorn, J.J., Koppel, J., Christen, E., 2014. APOE genotype modulates proton magnetic
679 resonance spectroscopy metabolites in the aging brain. *Biol. Psychiatry* 75, 686–692.
- 680 Gorno-Tempini, M.L., Dronkers, N.F., Rankin, K.P., Ogar, J.M., Phengrasamy, L., Rosen, H.J.,
681 Johnson, J.K., Weiner, M.W., Miller, B.L., 2004. Cognition and anatomy in three variants
682 of primary progressive aphasia. *Ann. Neurol.* 55, 335–346.
683 <https://doi.org/10.1002/ana.10825>
- 684 Gorno-Tempini, M.L., Hillis, A.E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S.F., Ogar,
685 J.M., Rohrer, J.D., Black, S., Boeve, B.F., 2011. Classification of primary progressive
686 aphasia and its variants. *Neurology* 76, 1006–1014.
- 687 Griffith, H.R., den Hollander, J.A., Okonkwo, O., Evanochko, W.T., Harrell, L.E., Zamrini, E.Y.,
688 Brockington, J.C., Marson, D.C., 2007. Executive function is associated with brain proton
689 magnetic resonance spectroscopy in amnesic mild cognitive impairment. *J. Clin. Exp.*
690 *Neuropsychol.* 29, 599–609.
- 691 Grossman, M., 2010. Primary progressive aphasia: clinicopathological correlations. *Nat. Rev.*
692 *Neurol.* 6, 88–97.

- 693 Haga, K.K., Khor, Y.P., Farrall, A., Wardlaw, J.M., 2009. A systematic review of brain metabolite
694 changes, measured with ¹H magnetic resonance spectroscopy, in healthy aging.
695 *Neurobiol. Aging* 30, 353–363.
- 696 Harris, A.D., Puts, N.A., Barker, P.B., Edden, R.A., 2015a. Spectral-editing measurements of
697 GABA in the human brain with and without macromolecule suppression. *Magn. Reson.*
698 *Med.* 74, 1523–1529.
- 699 Harris, A.D., Puts, N.A., Edden, R.A., 2015b. Tissue correction for GABA-edited MRS:
700 Considerations of voxel composition, tissue segmentation, and tissue relaxations. *J.*
701 *Magn. Reson. Imaging* 42, 1431–1440.
- 702 Harris, A.D., Saleh, M.G., Edden, R.A., 2017. Edited ¹H magnetic resonance spectroscopy in
703 vivo: Methods and metabolites. *Magn. Reson. Med.* 77, 1377–1389.
- 704 Harris, A.D., Wang, Z., Ficek, B., Webster, K., Edden, R.A., Tsapkini, K., 2019. Reductions in
705 GABA following a tDCS-language intervention for primary progressive aphasia.
706 *Neurobiol. Aging* 79, 75–82.
- 707 Hodges, J.R., Davies, R.R., Xuereb, J.H., Casey, B., Broe, M., Bak, T.H., Kril, J.J., Halliday,
708 G.M., 2004. Clinicopathological correlates in frontotemporal dementia. *Ann. Neurol.* 56,
709 399–406.
- 710 Huang, W., Alexander, G.E., Chang, L., Shetty, H.U., Krasuski, J.S., Rapoport, S.I., Schapiro,
711 M.B., 2001. Brain metabolite concentration and dementia severity in Alzheimer’s
712 disease: a ¹H MRS study. *Neurology* 57, 626–632.
- 713 Hui, S.C., Saleh, M., Zoellner, H.J., Oeltzschner, G., Fan, H., Li, Y., Song, Y., Jiang, H., Near,
714 J., Lu, H., 2022. MRSCloud: a Cloud-based MR Spectroscopy Tool for Basis Set
715 Simulation. *bioRxiv*.
- 716 Hupfeld, K.E., Hyatt, H.W., Alvarez Jerez, P., Mikkelsen, M., Hass, C.J., Edden, R.A.E., Seidler,
717 R.D., Porges, E.C., 2021. In vivo brain glutathione is higher in older age and correlates
718 with mobility. *Cereb. Cortex* 31, 4576–4594.
- 719 Josephs, K.A., Duffy, J.R., Strand, E.A., Whitwell, J.L., Layton, K.F., Parisi, J.E., Hauser, M.F.,
720 Witte, R.J., Boeve, B.F., Knopman, D.S., 2006. Clinicopathological and imaging
721 correlates of progressive aphasia and apraxia of speech. *Brain* 129, 1385–1398.
- 722 Kang, J.-S., Tian, J.-H., Pan, P.-Y., Zald, P., Li, C., Deng, C., Sheng, Z.-H., 2008. Docking of
723 axonal mitochondria by syntaphilin controls their mobility and affects short-term
724 facilitation. *Cell* 132, 137–148.
- 725 Kantarci, K., Lowe, V., Przybelski, S.A., Senjem, M.L., Weigand, S.D., Ivnik, R.J., Roberts, R.,
726 Geda, Y.E., Boeve, B.F., Knopman, D.S., 2011. Magnetic resonance spectroscopy, β -
727 amyloid load, and cognition in a population-based sample of cognitively normal older
728 adults. *Neurology* 77, 951–958.
- 729 Kaplan, E., Goodglass, F., Weintraub, S., 2001. Boston Naming Test. Pro-ed Austin.
- 730 Kim, G., Ahmadian, S.S., Peterson, M., Parton, Z., Memon, R., Weintraub, S., Rademaker, A.,
731 Bigio, E., Mesulam, M.-M., Geula, C., 2016. Asymmetric pathology in primary
732 progressive aphasia with progranulin mutations and TDP inclusions. *Neurology* 86, 627–
733 636.
- 734 Klose, U., 1990. In vivo proton spectroscopy in presence of eddy currents. *Magn. Reson. Med.*
735 14, 26–30.
- 736 Knibb, J.A., Xuereb, J.H., Patterson, K., Hodges, J.R., 2006. Clinical and pathological
737 characterization of progressive aphasia. *Ann. Neurol.* 59, 156–165.
- 738 Knopman, D.S., Kramer, J.H., Boeve, B.F., Caselli, R.J., Graff-Radford, N.R., Mendez, M.F.,
739 Miller, B.L., Mercaldo, N., 2008. Development of methodology for conducting clinical
740 trials in frontotemporal lobar degeneration. *Brain* 131, 2957–2968.
- 741 Levin, O., Weerasekera, A., King, B.R., Heise, K.F., Sima, D.M., Chalavi, S., Maes, C., Peeters,
742 R., Sunaert, S., Cuypers, K., 2019. Sensorimotor cortex neurometabolite levels as

- 743 correlate of motor performance in normal aging: evidence from a 1H-MRS study.
744 *NeuroImage* 202, 116050.
- 745 Liakakis, G., Nickel, J., Seitz, R., 2011. Diversity of the inferior frontal gyrus—a meta-analysis of
746 neuroimaging studies. *Behav. Brain Res.* 225, 341–347.
- 747 Lim, T.S., Hong, Y.H., Choi, J.Y., Kim, H.S., Moon, S.Y., 2012. Functional investigation of
748 bilateral posterior cingulate gyri using multivoxel MR spectroscopy. *Eur. Neurol.* 67,
749 279–286.
- 750 Lin, A., Andronesi, O., Bogner, W., Choi, I.-Y., Coello, E., Cudalbu, C., Juchem, C., Kemp, G.J.,
751 Kreis, R., Krššák, M., 2021. Minimum reporting standards for in vivo magnetic resonance
752 spectroscopy (MRSinMRS): experts' consensus recommendations. *NMR Biomed.* 34,
753 e4484.
- 754 Maes, C., Hermans, L., Pauwels, L., Chalavi, S., Leunissen, I., Levin, O., Cuypers, K., Peeters,
755 R., Sunaert, S., Mantini, D., 2018. Age-related differences in GABA levels are driven by
756 bulk tissue changes. *Hum. Brain Mapp.* 39, 3652–3662.
- 757 Marjańska, M., Emir, U.E., Deelchand, D.K., Terpstra, M., 2013. Faster metabolite 1H
758 transverse relaxation in the elder human brain. *PloS One* 8, e77572.
- 759 Marjańska, M., McCarten, J.R., Hodges, J., Hemmy, L.S., Grant, A., Deelchand, D.K., Terpstra,
760 M., 2017. Region-specific aging of the human brain as evidenced by neurochemical
761 profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe
762 using 1H magnetic resonance spectroscopy at 7 T. *Neuroscience* 354, 168–177.
- 763 Marjańska, M., McCarten, J.R., Hodges, J.S., Hemmy, L.S., Terpstra, M., 2019. Distinctive
764 neurochemistry in Alzheimer's Disease via 7 T in vivo magnetic resonance
765 spectroscopy. *J. Alzheimers Dis.* 68, 559–569.
- 766 McLeod, A.I., Xu, C., 2010. bestglm: Best subset GLM. URL [HttpCRAN R-Proj. Orgpackage](http://CRAN.R-project.org/package=Bestglm)
767 [Bestglm](http://CRAN.R-project.org/package=Bestglm).
- 768 Mescher, M., Merkle, H., Kirsch, J., Garwood, M., Gruetter, R., 1998. Simultaneous in vivo
769 spectral editing and water suppression. *NMR Biomed. Int. J. Devoted Dev. Appl. Magn.*
770 *Reson. Vivo* 11, 266–272.
- 771 Mesulam, M., 1982. Slowly progressive aphasia without generalized dementia. *Ann. Neurol. Off.*
772 *J. Am. Neurol. Assoc. Child Neurol. Soc.* 11, 592–598.
- 773 Mesulam, M., Wicklund, A., Johnson, N., Rogalski, E., Léger, G.C., Rademaker, A., Weintraub,
774 S., Bigio, E.H., 2008. Alzheimer and frontotemporal pathology in subsets of primary
775 progressive aphasia. *Ann. Neurol. Off. J. Am. Neurol. Assoc. Child Neurol. Soc.* 63,
776 709–719.
- 777 Mikkelsen, M., Tapper, S., Near, J., Mostofsky, S.H., Puts, N.A., Edden, R.A., 2020. Correcting
778 frequency and phase offsets in MRS data using robust spectral registration. *NMR*
779 *Biomed.* 33, e4368.
- 780 Mitolo, M., Stanzani-Maserati, M., Manners, D.N., Capellari, S., Testa, C., Talozzi, L., Poda, R.,
781 Oppi, F., Evangelisti, S., Gramegna, L.L., Magarelli, S., Pantieri, R., Liguori, R., Lodi, R.,
782 Tonon, C., 2021. The Combination of Metabolic Posterior Cingulate Cortical
783 Abnormalities and Structural Asymmetries Improves the Differential Diagnosis Between
784 Primary Progressive Aphasia and Alzheimer's Disease. *J. Alzheimers Dis.* 82, 1467–
785 1473. <https://doi.org/10.3233/JAD-210211>
- 786 Mosser, D.M., Edwards, J.P., 2008. Exploring the full spectrum of macrophage activation. *Nat.*
787 *Rev. Immunol.* 8, 958–969.
- 788 Murley, A.G., Rouse, M.A., Jones, P.S., Ye, R., Hezemans, F.H., O'Callaghan, C., Frangou, P.,
789 Kourtzi, Z., Rua, C., Carpenter, T.A., 2020. GABA and glutamate deficits from
790 frontotemporal lobar degeneration are associated with disinhibition. *Brain* 143, 3449–
791 3462.

- 792 Murley, A.G., Tsvetanov, K.A., Rouse, M.A., Jones, P.S., Sværke, K., Li, W., Carpenter, A.,
793 Rowe, J.B., 2022. Proton magnetic resonance spectroscopy in frontotemporal lobar
794 degeneration-related syndromes. *Neurobiol. Aging* 111, 64–70.
- 795 Nestor, P.J., Balan, K., Cheow, H.K., Fryer, T.D., Knibb, J.A., Xuereb, J.H., Hodges, J.R., 2007.
796 Nuclear imaging can predict pathologic diagnosis in progressive nonfluent aphasia.
797 *Neurology* 68, 238–239.
- 798 Nwaroh, C., Giuffre, A., Cole, L., Bell, T., Carlson, H.L., MacMaster, F.P., Kirton, A., Harris,
799 A.D., 2020. Effects of Transcranial Direct Current Stimulation on GABA and Glx in
800 Children: A pilot study. *PLOS ONE* 15, e0222620.
801 <https://doi.org/10.1371/journal.pone.0222620>
- 802 Oeltzschner, G., Wijtenburg, S.A., Mikkelsen, M., Edden, R.A., Barker, P.B., Joo, J.H.,
803 Leoutsakos, J.-M.S., Rowland, L.M., Workman, C.I., Smith, G.S., 2019.
804 Neurometabolites and associations with cognitive deficits in mild cognitive impairment: a
805 magnetic resonance spectroscopy study at 7 Tesla. *Neurobiol. Aging* 73, 211–218.
- 806 Oeltzschner, G., Zöllner, H.J., Hui, S.C., Mikkelsen, M., Saleh, M.G., Tapper, S., Edden, R.A.,
807 2020. Osprey: Open-source processing, reconstruction & estimation of magnetic
808 resonance spectroscopy data. *J. Neurosci. Methods* 343, 108827.
- 809 Ohm, D.T., Kim, G., Gefen, T., Rademaker, A., Weintraub, S., Bigio, E.H., Mesulam, M.-M.,
810 Rogalski, E., Geula, C., 2019. Prominent microglial activation in cortical white matter is
811 selectively associated with cortical atrophy in primary progressive aphasia. *Neuropathol.*
812 *Appl. Neurobiol.* 45, 216–229.
- 813 Pagnoni, I., Gobbi, E., Premi, E., Borroni, B., Binetti, G., Cotelli, M., Manenti, R., 2021.
814 Language training for oral and written naming impairment in primary progressive
815 aphasia: A review. *Transl. Neurodegener.* 10, 1–34.
- 816 Pfefferbaum, A., Adalsteinsson, E., Spielman, D., Sullivan, E.V., Lim, K.O., 1999. In vivo
817 spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large
818 volumes of brain gray and white matter: Effects of normal aging. *Magn. Reson. Med. Off.*
819 *J. Int. Soc. Magn. Reson. Med.* 41, 276–284.
- 820 Pinheiro, J.C., Bates, D.M., 2000. Theory and computational methods for linear mixed-effects
821 models. *Mix.-Eff. Models -PLUS* 57–96.
- 822 Porges, E.C., Woods, A.J., Edden, R.A., Puts, N.A., Harris, A.D., Chen, H., Garcia, A.M.,
823 Seider, T.R., Lamb, D.G., Williamson, J.B., 2017a. Frontal gamma-aminobutyric acid
824 concentrations are associated with cognitive performance in older adults. *Biol.*
825 *Psychiatry Cogn. Neurosci. Neuroimaging* 2, 38–44.
- 826 Porges, E.C., Woods, A.J., Lamb, D.G., Williamson, J.B., Cohen, R.A., Edden, R.A., Harris,
827 A.D., 2017b. Impact of tissue correction strategy on GABA-edited MRS findings.
828 *Neuroimage* 162, 249–256.
- 829 Preiß, D., Billette, O.V., Schneider, A., Spotorno, N., Nestor, P.J., 2019. The atrophy pattern in
830 Alzheimer-related PPA is more widespread than that of the frontotemporal lobar
831 degeneration associated variants. *NeuroImage Clin.* 24, 101994.
832 <https://doi.org/10.1016/j.nicl.2019.101994>
- 833 R Core Team, 2021. R: A language and environment for statistical computing. R Foundation for
834 Statistical Computing, Vienna, Austria.
- 835 Rabinovici, G.D., Jagust, W.J., Furst, A.J., Ogar, J.M., Racine, C.A., Mormino, E.C., O'Neil,
836 J.P., Lal, R.A., Dronkers, N.F., Miller, B.L., 2008. A β amyloid and glucose metabolism in
837 three variants of primary progressive aphasia. *Ann. Neurol.* 64, 388–401.
- 838 Rackayova, V., Cudalbu, C., Pouwels, P.J., Braissant, O., 2017. Creatine in the central nervous
839 system: From magnetic resonance spectroscopy to creatine deficiencies. *Anal. Biochem.*
840 529, 144–157.
- 841 Rae, C.D., 2014. A guide to the metabolic pathways and function of metabolites observed in
842 human brain ¹H magnetic resonance spectra. *Neurochem. Res.* 39, 1–36.

- 843 Ratai, E.-M., Annamalai, L., Burdo, T., Joo, C.-G., Bombardier, J.P., Fell, R., Hakimelahi, R.,
844 He, J., Lentz, M.R., Campbell, J., 2011. Brain creatine elevation and N-acetylaspartate
845 reduction indicates neuronal dysfunction in the setting of enhanced glial energy
846 metabolism in a macaque model of NeuroAIDS. *Magn. Reson. Med.* 66, 625–634.
- 847 Reyngoudt, H., Claeys, T., Vlerick, L., Verleden, S., Acou, M., Deblaere, K., De Deene, Y.,
848 Audenaert, K., Goethals, I., Achten, E., 2012. Age-related differences in metabolites in
849 the posterior cingulate cortex and hippocampus of normal ageing brain: a 1H-MRS
850 study. *Eur. J. Radiol.* 81, e223–e231.
- 851 Riese, F., Gietl, A., Zölch, N., Henning, A., O’Gorman, R., Kälin, A.M., Leh, S.E., Buck, A.,
852 Warnock, G., Edden, R.A., 2015. Posterior cingulate γ -aminobutyric acid and
853 glutamate/glutamine are reduced in amnesic mild cognitive impairment and are
854 unrelated to amyloid deposition and apolipoprotein E genotype. *Neurobiol. Aging* 36, 53–
855 59.
- 856 Rogalski, E., Cobia, D., Harrison, T.M., Wieneke, C., Weintraub, S., Mesulam, M.-M., 2011.
857 Progression of language decline and cortical atrophy in subtypes of primary progressive
858 aphasia. *Neurology* 76, 1804–1810. <https://doi.org/10.1212/WNL.0b013e31821ccd3c>
- 859 Rogalski, E., Cobia, D., Martersteck, A., Rademaker, A., Wieneke, C., Weintraub, S., Mesulam,
860 M.-M., 2014. Asymmetry of cortical decline in subtypes of primary progressive aphasia.
861 *Neurology* 83, 1184–1191.
- 862 Ross, A.J., Sachdev, P.S., Wen, W., Valenzuela, M.J., Brodaty, H., 2005. Cognitive correlates
863 of 1H MRS measures in the healthy elderly brain. *Brain Res. Bull.* 66, 9–16.
- 864 RStudio Team, 2021. RStudio: Integrated Development Environment for R. RStudio, PBC,
865 Boston, MA.
- 866 Rupsingh, R., Borrie, M., Smith, M., Wells, J.L., Bartha, R., 2011. Reduced hippocampal
867 glutamate in Alzheimer disease. *Neurobiol. Aging* 32, 802–810.
- 868 Sasaki, R., Otsuru, N., Miyaguchi, S., Kojima, S., Watanabe, H., Ohno, K., Sakurai, N.,
869 Kodama, N., Sato, D., Onishi, H., 2021. Influence of Brain-Derived Neurotrophic Factor
870 Genotype on Short-Latency Afferent Inhibition and Motor Cortex Metabolites. *Brain Sci.*
871 11, 395. <https://doi.org/10.3390/brainsci11030395>
- 872 Saunders, D.E., Howe, F.A., van den Boogaart, A., Griffiths, J.R., Brown, M.M., 1999. Aging of
873 the adult human brain: in vivo quantitation of metabolite content with proton magnetic
874 resonance spectroscopy. *J. Magn. Reson. Imaging Off. J. Int. Soc. Magn. Reson. Med.*
875 9, 711–716.
- 876 Tastevin, M., Lavoie, M., de la Sablonnière, J., Carrier-Auclair, J., Laforce, R., 2021. Survival in
877 the Three Common Variants of Primary Progressive Aphasia: A Retrospective Study in a
878 Tertiary Memory Clinic. *Brain Sci.* 11, 1113. <https://doi.org/10.3390/brainsci11091113>
- 879 Tkáč, I., Starčuk, Z., Choi, I.-Y., Gruetter, R., 1999. In vivo 1H NMR spectroscopy of rat brain at
880 1 ms echo time. *Magn. Reson. Med. Off. J. Int. Soc. Magn. Reson. Med.* 41, 649–656.
- 881 Tombaugh, T., 1999. Normative Data Stratified by Age and Education for Two Measures of
882 Verbal Fluency FAS and Animal Naming. *Arch. Clin. Neuropsychol.* 14, 167–177.
883 [https://doi.org/10.1016/S0887-6177\(97\)00095-4](https://doi.org/10.1016/S0887-6177(97)00095-4)
- 884 Tsapkini, K., Frangakis, C., Gomez, Y., Davis, C., Hillis, A.E., 2014. Augmentation of spelling
885 therapy with transcranial direct current stimulation in primary progressive aphasia:
886 Preliminary results and challenges. *Aphasiology* 28, 1112–1130.
887 <https://doi.org/10.1080/02687038.2014.930410>
- 888 Tsapkini, K., Webster, K.T., Ficek, B.N., Desmond, J.E., Onyike, C.U., Rapp, B., Frangakis,
889 C.E., Hillis, A.E., 2018. Electrical brain stimulation in different variants of primary
890 progressive aphasia: A randomized clinical trial. *Alzheimers Dement. Transl. Res. Clin.*
891 *Interv.* 4, 461–472.

- 892 Urenjak, J., Williams, S.R., Gadian, D.G., Noble, M., 1993. Proton nuclear magnetic resonance
893 spectroscopy unambiguously identifies different neural cell types. *J. Neurosci.* 13, 981–
894 989.
- 895 Wang, H., Tan, L., Wang, H.-F., Liu, Y., Yin, R.-H., Wang, W.-Y., Chang, X.-L., Jiang, T., Yu, J.-
896 T., 2015. Magnetic resonance spectroscopy in Alzheimer’s disease: systematic review
897 and meta-analysis. *J. Alzheimers Dis.* 46, 1049–1070.
- 898 Wansapura, J.P., Holland, S.K., Dunn, R.S., Ball Jr, W.S., 1999. NMR relaxation times in the
899 human brain at 3.0 tesla. *J. Magn. Reson. Imaging Off. J. Int. Soc. Magn. Reson. Med.*
900 9, 531–538.
- 901 Wicklund, M.R., Duffy, J.R., Strand, E.A., Machulda, M.M., Whitwell, J.L., Josephs, K.A., 2014.
902 Quantitative application of the primary progressive aphasia consensus criteria.
903 *Neurology* 82, 1119–1126. <https://doi.org/10.1212/WNL.0000000000000261>
- 904 Wilson, M., Andronesi, O., Barker, P.B., Bartha, R., Bizzi, A., Bolan, P.J., Brindle, K.M., Choi, I.-
905 Y., Cudalbu, C., Dydak, U., 2019. Methodological consensus on clinical proton MRS of
906 the brain: Review and recommendations. *Magn. Reson. Med.* 82, 527–550.
- 907 Zahr, N.M., Mayer, D., Rohlfing, T., Chanraud, S., Gu, M., Sullivan, E.V., Pfefferbaum, A., 2013.
908 In vivo glutamate measured with magnetic resonance spectroscopy: behavioral
909 correlates in aging. *Neurobiol. Aging* 34, 1265–1276.
- 910 Zeydan, B., Deelchand, D.K., Tosakulwong, N., Lesnick, T.G., Kantarci, O.H., Machulda, M.M.,
911 Knopman, D.S., Lowe, V.J., Jack Jr, C.R., Petersen, R.C., 2017. Decreased glutamate
912 levels in patients with amnesic mild cognitive impairment: An sLASER proton MR
913 spectroscopy and PiB-PET study. *J. Neuroimaging* 27, 630–636.
- 914 Zhang, N., Song, X., Bartha, R., Beyea, S., D’Arcy, R., Zhang, Y., Rockwood, K., 2014.
915 Advances in high-field magnetic resonance spectroscopy in Alzheimer’s disease. *Curr.*
916 *Alzheimer Res.* 11, 367–388.
- 917 Zhang, Z., 2016. Variable selection with stepwise and best subset approaches. *Ann. Transl.*
918 *Med.* 4.
- 919 Zöllner, H.J., Považan, M., Hui, S.C., Tapper, S., Edden, R.A., Oeltzschner, G., 2021.
920 Comparison of different linear-combination modeling algorithms for short-TE proton
921 spectra. *NMR Biomed.* 34, e4482.
- 922 Zöllner, H.J., Tapper, S., Hui, S.C., Barker, P.B., Edden, R.A., Oeltzschner, G., 2022.
923 Comparison of linear combination modeling strategies for edited magnetic resonance
924 spectroscopy at 3 T. *NMR Biomed.* 35, e4618.
- 925